



\$385-201 08/736019 #Seg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Doc. No.: CNS 5250.26-JEL/MFB

Anticipated Art Group: 1812

Date: October 22, 1996

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S I R:

This is a request for filing a

(X) Continuation application under 37 CFR 1.60;

() Division application under 37 CFR 1.60,

of pending prior application Serial No. 08/471,833
filed on June 6, 1995

Andrew Goodearl, et al.

(inventors)

for GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE

(title of invention)

ATTACHED IS A TRUE COPY OF SAID PRIOR APPLICATION AS FILED
from the records of the Attorney of Record.

The filing fee is calculated below:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT BELOW

For	Number Filed	Number Extra	Rate	Basic fee (\$770/385)
Total Claims.....	9	0	x \$22/11 =	\$
Independent Claims.	3	0	x \$80/40 =	\$

() Multiple Dependent Claims - where applicable (\$260/130)
() Foreign language text - where applicable (\$130)

TOTAL FILING FEE

\$385.00

(X) The filing fee of \$385.00 is enclosed. In the event the enclosed check is unacceptable and/or insufficient to cover the required fees, please charge to account No. 06-0530.

Cont'd

08/736019-102996

1. (X) Amend the specification by inserting before the first line the sentence: -- This application is a continuation of copending application Serial No. 08/471,833, filed June 6, 1995, which is a divisional of copending application Serial No. 08/036,555 filed March 24, 1993 (now U.S. Patent No. 5,530,555), which is a continuation-in-part of Serial No. 07/863,703 filed April 3, 1992 (abandoned), which in turn is a continuation-in-part of Serial No. 07/907,138 filed June 30, 1992 (abandoned), which is a continuation-in-part of Serial No. 07/940,389 filed September 3, 1992 (abandoned), which is a continuation-in-part of Serial No. 07/965,173 filed October 23, 1992 (abandoned). --.

- 2a. (X) Priority is hereby claimed under 35 USC 119 on the basis of United Kingdom Application Serial No. 91 07566.3 filed on April 10, 1991.

- 2b. (X) The priority document (2a) was filed in the parent application Serial No. 08/036,555, filed March 24, 1993; and filing of the priority document was acknowledged in a communication from the Patent Office on Nov. 29, 1995 in application Serial No. 08/471,833.

- 3a. () Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

- 3b. () New formal drawings are enclosed.

4. (X) The prior application is assigned to Cambridge NeuroScience, One Kendall Square, Cambridge, MA 02139 and Ludwig Institute for Cancer Research, 1345 Avenue of the Americas, New York, N.Y. 10105.

5. (X) The power of attorney in the prior application is to John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Alfred H. Hemingway, Jr., Reg. No. 26,736; Vincent M. Fazzari, Reg. No. 26,879; Norman D. Hanson, Reg. No. 30,946; F. Brice Faller, Reg. No. 29,532; Andrew L. Tiajolloff, Reg. No. 31,575; and John A. Bauer, Reg. No. 32,554, my attorneys with full power of substitution and revocation.

Address all correspondence to: FELFE & LYNCH
805 Third Avenue
New York, New York 10022
(Telephone: 212-688-9200)

- 6a. (X) Cancel claims 1-131 without prejudice.

Page 3

Docket No.: CNS 5250.26-JEL/MFB

Anticipated Art Group: 1812

Date: October 22, 1996

- 6b. (X) Preliminary Amendment.
6c. (X) Associate Power of Attorney.

Respectfully submitted,

FELFE & LYNCH

By Madeline F. Baer
Madeline F. Baer
Reg. No. 36,437

805 Third Avenue
New York, N.Y. 10022
(212) 688-9200

Enclosure

(X) Duplicate () Triplicate

962201 6T09E/3B